Tag: Augtyro for NSCLC

Home / Augtyro for NSCLC

Categories

Repotrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer

The Food and Drug Administration authorized repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) on November 15, 2...
augtyro-for-nsclc

Scan the code